Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells

Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, but inherent and acquired resistance to the drug remains a problem. We here sho...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Starheim, K K, Holien, T, Misund, K, Johansson, I, Baranowska, K A, Sponaas, A-M, Hella, H, Buene, G, Waage, A, Sundan, A, Bjørkøy, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5141348/
https://ncbi.nlm.nih.gov/pubmed/27421095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.56
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados